Month: January 2017

APT Therapeutics Inc. Enters Global Collaboration, Option and Asset Purchase Agreement to Study Human Apyrase Therapy

ST. LOUIS – (COMMERCIAL THREAD) – APT Therapeutics, Inc., a privately held biopharmaceutical company, today announced a collaborative research, option and asset purchase agreement with AstraZeneca. APT Therapeutics applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Unique different from current FDA-approved antithrombotic drugs that […]

Back To Top